Australia markets closed

Zealand Pharma A/S (22Z.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
90.50-0.75 (-0.82%)
As of 04:32PM CET. Market open.
Full screen
Previous close91.25
Open91.60
Bid90.60 x 200000
Ask92.10 x 388000
Day's range89.60 - 91.60
52-week range27.40 - 103.10
Volume359
Avg. volume286
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

    Company announcement – No. 20 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, March 26, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securiti

  • GlobeNewswire

    Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

    Company announcement – No. 19 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, March 26, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 32,808 divided into 32,808 new shares with a nominal value of DKK 1 each. The incre

  • GlobeNewswire

    Zealand Pharma major shareholder announcement: Van Herk Investments

    Company announcement – No. 18 / 2024 Zealand Pharma major shareholder announcement: Van Herk Investments Copenhagen, Denmark, 21 March 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 21 March 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders: As of 20 Ma